Trimetazidine (Di HCl)

Overview

Moexipril is an oral angiotensin-converting enzyme (ACE) inhibitor and is used to treat hypertension. Like quinapril and ramipril, the active metabolite is produced by deesterification from the prodrug. Moexiprilat (the deesterified form), is about 1000 times active than moexipril itself and antihypertensive activity entirely depends on this metabolite. Prolonged antihypertensive effects allow for once-daily dosing. The dosage range is halved in patients who are taking diuretics or who have renal impairment. It was approved by FDA on April 19, 1995.

Categories

Primary Characterstics

Molecular Structure of Trimetazidine (Di HCl)

belongs to Piperazine. It belongs to Antianginal Agents pharmacological group.The Molecular Weight of Trimetazidine (Di HCl) is 339.30.

Indications

Back to top

Pharmacokinetics

Back to top

Contraindications

Back to top

Drug Interactions

Back to top

Side Effects

Back to top

Dosage

Moexipril's dosage details are as follows:
Dose Single Dose Frequency Route Instructions

Adult Dosage

20 mg20 (20)8 hourlyPO

Paedriatic Dosage (20kg)

Not recommended in this age group

Neonatal Dosage (3kg)

Not recommended in this age group

High Risk Groups

Back to top

Warning / Precautions

Back to top

Storage Conditions

Back to top

Interference in Pathology

No data regarding the pathological interferences produced by Trimetazidine (Di HCl) is available.

Back to top

Brands / Trade Names of Moexipril

Back to top

Manufacturers of Trimetazidine (Di HCl) in Pakistan

Back to top

Previous Drug Generic - Next Drug Generic


Suggested Pages